USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility

The USFDA had classified the inspection as "Official Action Indicated" (OAI).

Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices

Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.

Sun Pharmaceutical gets OAI from USFDA for Mohali facility

Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr

It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio

Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr

The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.

Biopharma funding rebounds in 2026, but capital flows to lower-risk assets

M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges

Sun Pharma to acquire Innovcare Lifesciences for Rs. 271.2 crore

Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026

Alembic appoints Ramesh Juneja as Executive Vice President – Human Health for India business

Juneja brings more than three decades of experience in pharmaceutical sales and marketing